Biotech patent strategy has always involved a little time travel. You file early, collect data later, refine claims after that, and then try to make your patent portfolio line up with science, regulation, funding, and commercial reality without spilling coffee on the docket. For years, continuation practice helped make that juggling act possible. It gave biotech applicants room to keep a family alive while the invention matured and the market came into focus.

Now the U.S. Patent and Trademark Office has made that flexibility more expensive. The new continuation application fee, effective in 2025, may look like just another line item on a patent budget. In reality, it can reshape filing behavior, compress decision-making, and create priority-claim risk at exactly the moment many biotech companies can least afford a paperwork ambush.

That is why this rule matters. In biotech, patent value often depends not just on the first filing, but on how thoughtfully a portfolio is extended over time. A late continuation can preserve optionality, support licensing, protect a lead asset, or keep claims aligned with fresh data. But under the new fee framework, waiting too long can mean higher costs, tighter deadlines, and, in some circumstances, a very unpleasant surprise on the filing receipt.

What Changed at the USPTO?

The headline change is simple: certain continuing applications now trigger an added fee when they are filed too far from the family’s earliest benefit date. The rule applies to utility, plant, and design continuing applications, including continuations, divisionals, and continuations-in-part. For undiscounted entities, the added fee is $2,700 when the application or benefit claim is presented more than six years after the earliest benefit date, and $4,000 when it is more than nine years after that date. Small and micro entities get reduced amounts, but the cost is still large enough to alter filing strategy.

The crucial phrase is earliest benefit date, or EBD. In plain English, that is the earliest filing date in the chain for which benefit is claimed under the continuation-style statutes. It is not the filing date of a foreign application, and it is not the filing date of a provisional application for this purpose. For utility and plant cases, it is also tied to the date from which the 20-year patent term is measured. So the fee clock is not just an accounting issue. It is connected to the life cycle of the application family itself.

The USPTO did not create this fee just to annoy biotech counsel on a Friday afternoon, although it may have that side effect. The agency has said the rapid growth in continuing applications has strained workload and docketing practices, and it has used its fee-setting authority to push applicants toward earlier and more efficient prosecution choices. In other words, the fee is also a behavior-shaping tool.

Why Biotech Feels the Pain More Than Many Other Sectors

Biotech applicants are unusually exposed because biotech timelines are unusually stubborn. Drug discovery does not care that a fee milestone is approaching. Clinical evidence does not appear on command. Regulatory paths shift. Claim strategy evolves as mechanism-of-action data, safety signals, dosage information, formulation work, manufacturing methods, and companion-diagnostic angles become clearer.

That is why continuation-heavy practice is so common in life sciences. A biotech company may start with a broad platform filing, then later pursue narrower species claims, method-of-treatment claims, formulation claims, dosing-regimen claims, manufacturing claims, or patient-selection claims as the science hardens. Each one can matter. Each one may become more valuable than the original claim set. And each one may arrive after years of prosecution, experimentation, or business development.

The timing problem gets worse in globally filed cases. Many biotech inventions enter the United States through the PCT national stage, which already consumes substantial time before ordinary U.S. prosecution even gets going. By the time the first office action arrives, and by the time the parent finally reaches allowance, the six-year mark may no longer be a distant concern. It may be standing in the lab doorway asking for a credit card.

For startups, universities, and emerging biotech companies, this timing mismatch can be brutal. The portfolio may need to stay alive because the company is still validating the lead program or courting investors. Yet the very period in which patience is commercially necessary is the period that can now trigger new continuation costs.

The Biggest Risks for Biotech Applicants

1. Rising Portfolio Costs at the Worst Possible Time

The first risk is obvious but still serious: money. Biotech applicants already operate in one of the most expensive corners of patent practice. Filing, sequence work, office action responses, foreign prosecution, excess-claim fees, maintenance fees, and transactional diligence already create a pricey ecosystem. Add a continuation fee on top of regular filing and examination costs, and the economics of keeping a family alive can shift fast.

That matters because biotech portfolios are rarely built around one-and-done filings. A company with one important platform family may need multiple continuations to cover compositions, methods, formulations, combinations, manufacturing steps, biomarkers, and treatment subpopulations. The new fee does not automatically kill those filings, but it can force companies to narrow the list sooner and more aggressively.

2. Silent Priority Trouble

The scarier risk is not just paying more. It is paying too little, too late, or not noticing that the priority claim was not entered. The continuation application fee is part of the requirements for presenting the benefit claim. If the required fee is not paid when due, the consequence is non-entry of the entire benefit claim. That is not a typo. The claim to priority can simply fail to enter.

Practically speaking, this creates a trap for the old “no-fee continuation” habit. Some applicants file first and defer some fees until later, using the extra time to decide whether to pursue the application and which claims to prosecute. Under the new rule, that habit can backfire when a CAF-triggering benefit claim is involved. The filing receipt may omit the priority claim, and the applicant may not receive a dramatic red-flag notice saying, “Congratulations, your continuity plan is on fire.” The burden is on the filer to check the receipt carefully and fix the problem promptly.

3. Weaker Lifecycle Management

Biotech patents are often managed as living assets. A continuation can be the bridge between early discovery and later commercial specificity. If the new fee causes applicants to skip a continuation they otherwise would have filed, the portfolio may lose claim flexibility exactly when a product becomes more valuable. That can affect exclusivity planning, partnering leverage, and enforcement posture.

In pharma and biologics, where a lead asset can take years to mature, the long runway was once inconvenient but manageable. Now it can be both inconvenient and taxable. The fee is not merely financial friction. It can change what gets claimed, when it gets claimed, and whether it gets claimed at all.

4. Harder Due Diligence in Deals and Financing

In biotech transactions, investors and acquirers do not just ask whether patents exist. They ask whether the claim strategy is coherent, whether priority chains are sound, whether key continuations are still possible, and whether copendency has been preserved. A missed fee, a missing benefit claim, or a last-minute scramble to re-present priority can become a diligence headache.

That is especially true where portfolio value depends on future claim drafting rather than already issued claims. If a buyer expected continuation optionality and discovers that the file history is messy, costlier, or less flexible than expected, valuation discussions can get awkward in a hurry.

5. More Pressure From Faster Patent Issuance

As if biotech teams needed one more stopwatch, the USPTO also accelerated patent issue timing in 2025. That means there is less room between issue notification and issuance for a leisurely continuation decision. In the old days, procrastination was still a bad strategy, but it had a little more oxygen. Now the window is tighter. If the parent is about to issue and the continuation decision is still floating around in an inbox labeled “circle back,” that is not strategy. That is portfolio roulette.

Examples of How the Rule Can Hit Real Biotech Programs

Example one: the antibody startup. A small biotech files an early platform application covering a class of antibodies. Several years later, preclinical data identifies two standout candidates and a cleaner epitope story. The company wants a continuation focused on narrower composition and treatment claims. By then, the earliest benefit date is more than six years old. The continuation is still worth filing, but the budget now has to absorb the new fee at the same time the company is paying for more experiments and gearing up for fundraising.

Example two: the university spinout. A university-originated family moves from broad discovery claims to manufacturing and formulation work after a spinout forms. The company wants to keep the family alive while negotiating with partners. The continuation strategy makes business sense, but the dates do not cooperate. The six-year milestone arrives before the partnering story is fully baked, which means timing pressure lands before financing certainty does.

Example three: the diagnostic case. A company begins with biomarker discoveries, then later learns which patient subgroups and assay thresholds matter commercially. The most valuable claim set may not be obvious until later clinical work. If counsel waits until allowance in the parent to file the continuation, the family may already be in fee-trigger territory. The science matured on schedule. The budget did not.

How Biotech Applicants Should Respond

Audit Families by the Six-Year and Nine-Year Marks

This is no longer optional housekeeping. Every important family should be tracked against the earliest benefit date, not just the immediate parent filing date that people casually remember. The six-year and nine-year milestones should be docketed and reviewed early. Not “sometime this quarter.” Early.

Decide on Continuations Before Allowance Fever Sets In

Too many continuation decisions historically happened when allowance arrived and everyone suddenly became philosophical. Under the new fee landscape, biotech applicants should review key families before allowance and before the issue-fee stage. That is even more important now that issuance can happen faster.

Review Filing Receipts Like They Matter, Because They Do

A filing receipt is not decorative. It is where applicants can confirm whether the benefit claim was entered. If the priority information is missing, the problem should be escalated immediately. A quiet omission can become a loud dispute later.

Coordinate Scientists, Business Teams, and Patent Counsel Earlier

The best continuation decisions do not happen in a patent silo. They happen when patent counsel knows what new data is coming, management knows which assets matter most, and business teams know which claims could support partnering, exclusivity, reimbursement, or enforcement goals. The fee rule makes early coordination more valuable because delay now carries a clearer price.

Budget for Optionality Instead of Pretending Optionality Is Free

For years, some applicants treated late continuation flexibility as a nearly default feature of U.S. practice. It is still available, but it is not free. Biotech companies should budget for that reality, especially in high-value families. Optionality remains useful. It just has a cover charge now.

Field Notes: Composite Experiences From the Biotech Side of the Table

The following experiences are composite, anonymized scenarios drawn from common patterns in biotech patent practice. They are not client-specific stories, but they reflect the kind of real-world tension the new continuation fee creates.

One common experience is the startup that files early because investors demand speed, then spends the next several years proving the science deserves the broadest protection it can realistically get. At the beginning, the company is thrilled just to have a filing date. By year five, the founders have better data, a clearer lead program, and more confidence about commercial direction. By year six, they also have a new fee problem. The patent team is no longer asking only, “What claims do we want?” It is also asking, “Which of these claims justify another several thousand dollars right now?” That shift can make the portfolio more disciplined, but it can also make it more conservative at precisely the wrong moment.

Another familiar experience is the licensing discussion where the patent family looks promising, but the continuation roadmap is still the real prize. The licensee is less interested in the exact issued claims on day one than in what future claims might be built around dosing, formulation, combinations, patient subsets, or manufacturing. Under the new rule, the question becomes more pointed: is the continuation strategy already funded and planned, or is it a vague hope parked in a spreadsheet? A family that once felt flexible can suddenly feel exposed if nobody tracked the earliest benefit date carefully.

Then there is the “no-fee continuation” reflex. For years, some teams liked the breathing room that came from filing first and refining later. In biotech, that breathing room could be genuinely useful because a few extra months might bring a decisive experiment, a key collaboration result, or a better sense of which embodiment mattered most. The new fee structure changes the emotional texture of that move. What used to feel clever can now feel risky. The moment a filing receipt comes back without the expected priority information, the room gets very quiet. Nobody is thinking about elegant strategy anymore. Everybody is thinking about cleanup.

A fourth experience is the late-stage parent that is suddenly moving toward issuance faster than expected. The prosecution team knows a continuation should probably be filed. The scientists are still arguing over what the next claim set should emphasize. The business team wants claims that map to the product roadmap. Management wants a recommendation by tomorrow morning. This is where the new continuation fee and faster issue timing work together to create pressure. Decisions that once could drift for a few extra weeks now need sharper discipline. The companies that handle this best are not necessarily the ones with the biggest budgets. They are the ones that built an earlier review process and made continuation planning part of ordinary portfolio management instead of emergency triage.

Conclusion

The new USPTO continuation fee is more than an administrative tweak. For biotech applicants, it creates a meaningful strategic fork in the road. The rule raises the cost of waiting, increases the importance of tracking the earliest benefit date, and turns routine continuation habits into decisions that require more planning and more precision.

That does not mean biotech applicants should stop filing continuations. Quite the opposite. In many families, continuations will remain essential. But the days of treating late continuation practice as cheap insurance are over. The smarter approach is to identify important families earlier, decide earlier, budget earlier, and verify priority claims immediately. In biotech, time has always been expensive. The USPTO has now made it officially billable.